ClinicalTrials.gg

Program

STSP-0601

A development code. Also written as “STSP-0601 for Injection”.

Its studies are mostly in Hemophilia A, led by 2 companies.

Furthest: phase 3, since Aug 25, 20215 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Staidson (Beijing) Biopharmaceuticals40 open or runningphase 2since Aug 25, 2021Feb 5, 2021none ahead
Jiangsu BioJeTay Biotechnology11 open or runningphase 3since Mar 13, 2025Mar 13, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2021First study: phase 1 study in Hemophilia ANew to Staidson (Beijing) BiopharmaceuticalsStaidson (Beijing) Biopharmaceuticals · NCT04747964 · 16 enrolled · China
  2. Aug 25, 2021Phase 2 study in Hemophilia AStaidson (Beijing) Biopharmaceuticals · NCT05027230 · 77 enrolled · China
  3. Nov 9, 2022Phase 2 study in Hemophilia AStaidson (Beijing) Biopharmaceuticals · NCT05619926 · 32 enrolled · China
  4. Feb 23, 2024Phase 2 study in Hemophilia AStaidson (Beijing) Biopharmaceuticals · NCT06289166 · 25 enrolled · China
  5. Mar 13, 2025Jiangsu BioJeTay Biotechnology's first study: phase 3 study in Hemophilia ANew to Jiangsu BioJeTay BiotechnologyJiangsu BioJeTay Biotechnology · NCT06922045 · 40 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06922045Hemophilia A · China3Active, not recruitingJiangsu BioJeTay BiotechnologySep 202640
NCT06289166Hemophilia A · China2CompletedStaidson (Beijing) BiopharmaceuticalsOct 17, 202425
NCT05619926Hemophilia A · China2CompletedStaidson (Beijing) BiopharmaceuticalsAug 25, 202332
NCT05027230Hemophilia A · China2CompletedStaidson (Beijing) BiopharmaceuticalsJul 15, 202377
NCT04747964Hemophilia A · China1CompletedStaidson (Beijing) BiopharmaceuticalsApr 19, 202116

How it is read

Names in the registry

  • “STSP-0601 for Injection”, 11 entries

Codes read as this program: STSP0601.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.